Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer (Q37012007)

17 August 2017

1 reference

title

Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer (English)

1 reference

17 August 2017

1 reference

Marie-Christine Etienne-Grimaldi

1

1 reference

17 August 2017

Mireille Francoual

2

1 reference

17 August 2017

Jean-Louis Formento

3

1 reference

17 August 2017

Gérard Milano

4

1 reference

17 August 2017

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1561-1566

1 reference

Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Molecular genetics of methylenetetrahydrofolate reductase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Biological and clinical implications of the MTHFR C677T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Expression and clinical significance of methylenetetrahydrofolate reductase in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

Pharmacogenomics of thymidylate synthase in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1561

10.2217/14622416.8.11.1561

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference